Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
interferon gamma
- Development stage
- Unknown
- Lead developer
- Guna
- Modality
- Hormonal Peptides → Native Peptides → Peptides, Hormones & Growth Factors → Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Oral
01
Overview
Guna-IFN γ is a low-dose pharmaceutical formulation of recombinant human interferon-gamma (IFN-γ) developed by Guna S.p.a. using Sequential Kinetic Activation (SKA) technology. This formulation delivers the cytokine at physiological concentrations (typically in the picogram to femtogram per milliliter range), intended to modulate the immune system rather than provide the high-dose pharmacological effects associated with conventional interferon therapy. The mechanism of action focuses on enhancing Natural Killer (NK) cell cytotoxicity and balancing the Th1/Th2 immune response. It is primarily investigated for its immunomodulatory potential in treating allergic asthma, eczema (atopic dermatitis), and as an adjuvant therapy in colorectal cancer. Additionally, it has been studied in veterinary medicine for managing feline herpesvirus 1 (FHV-1) infections.
- Brand names
- Guna-IFN γ
- Other names
- Low-dose interferon gammaGuna-IFN-gammaInterferon gamma SKA
02
Targets
HS (Heparan sulfate)IFNGR1 (Interferon gamma receptor 1)IFNGR2 (Interferon gamma receptor 2)
Beyond the preview
Go deeper on interferon gamma.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on interferon gamma.